Kahn Brothers’ Top Stock Picks For Q3

Irving and Thomas Kahn are value investors who have been running their investment firm since 1978. Irving Kahn was one of legendary value investor Benjamin Graham’s students, and the firm’s emphasis on a stock’s pricing relative to its book value and historical earnings is much in line with that tradition. In early November Kahn Brothers filed its 13F for the third quarter of 2012, which discloses many of its long equity positions as of the end of September. Read on for our quick take on its top five holdings and compare their picks to previous filings.

Irving Kahn

The fund’s top pick was pharmaceutical manufacturer Pfizer Inc. (NYSE:PFE), with Kahn Brothers reporting a position of 2.5 million shares- essentially unchanged from three months earlier. The $184 billion market cap giant reported earnings growth of 25% in its most recent quarterly report compared to the same period in 2011 despite somewhat lower revenue. It trades at 18 times trailing earnings, but an optimistic analyst group projects continued strong growth that implies a forward P/E of only 11. With a 3.5% dividend yield as well, Pfizer’s got our attention; however, we’d need to do due diligence on that projected path to such an attractive P/E multiple. Billionaire Ken Fisher’s Fisher Asset Management has been another large investor in Pfizer.

New York Community Bancorp, Inc. (NYSE:NYB) was another of Kahn Brothers’ favorite stocks, though as with Pfizer the fund’s position was more or less unchanged at 3.6 million shares. The retail bank holding company trades at somewhat higher P/E and P/B multiples than many large banks- it is priced at 1.1 times the book value of its equity, and 12 times trailing earnings- but on an absolute basis New York Community Bancorp does not look particularly overpriced. The stock also offers a 7.2% dividend yield, having paid a 25 cent per share dividend every quarter since April 2004. Value investors should look at other banks, but income investors should take it into consideration.

Kahn Brothers’ position in Merck & Co., Inc. (NYSE:MRK) was also kept steady at 1.1 million shares. Like Pfizer, Merck is not a particularly good value stock when looking at trailing earnings- the P/E multiple is 21- but if Wall Street analysts are right then the company is in for some very good quarters that will bring its earnings up. That P/E becomes 12 on the basis of forward estimates. Merck’s dividend yield is also good, at 4.5%. As with Pfizer, we like that pricing as long as the company can deliver on those earnings targets- and would like to check the company out more closely.

The firm did slightly increase its stake in, of all things, The New York Times Company (NYSE:NYT), with the 4.7 million shares in its portfolio at the end of September being just a bit higher than the 4.6 million that it had owned three months earlier. The New York Times experienced a 16% decline in revenue in the third quarter of the year versus Q3 2011, which contributed to an 86% decrease in earnings over the same period. At 17 times consensus earnings for 2013- a figure which reflects a dramatic improvement in its business- we don’t think that investors should be buying.

Citigroup Inc. (NYSE:C) gave Kahn Brothers some exposure to the big banks in the second quarter, when the firm had bought the stock heavily, and it broke into the top five holdings in the 13F portfolio by the end of the third quarter. The megabank is getting a new CEO with the departure of Vikram Pandit, and is up 33% year to date. This has brought it to a multiple of 8 times expected earnings for next year, which we’d normally consider to be value territory, and it also trades at a steep discount to book value. We looked at Citi recently and decided that investors could buy it, JPMorgan Chase, or Wells Fargo depending on how much they valued low multiples versus safety and stability. Read our recent analysis of Citigroup.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!